The numbers are in, and they spell change for life sciences. 

That’s because nearly three-quarters (73%) of global pharmaceutical organizations are actively planning, piloting, or deploying agentic AI initiatives. 

This widespread means agentic AI is no longer a futuristic concept, but a present-day imperative for staying competitive and delivering life-changing medicines faster.

For those not yet in the know, agentic AI is a sophisticated form of AI designed not just to analyze data, but to act autonomously, plan, reason, and execute complex, multi-step tasks. This goes far beyond traditional automation. Instead, agentic AI is about creating intelligent systems that can drive innovation, accelerate drug development, and optimize operations like never before.

So, which companies are leading the charge, and how exactly are these intelligent agents reshaping the pharma landscape? Let's dive into the specifics.

Leading the charge: Pharma giants embracing agentic AI

Several major pharmaceutical companies and innovative service providers are at the forefront of integrating agentic AI into their core operations. Their strategies offer a glimpse into the future of intelligent pharma.

‍Johnson & Johnson (J&J): Pioneering autonomous drug discovery

Johnson & Johnson is a prime example of a pharma leader leveraging agentic AI for fundamental scientific advancements. They are deploying agentic AI systems specifically for autonomous drug discovery. Imagine a system that can not only identify potential drug candidates but also determine the optimal timing for critical steps in chemical synthesis, such as solvent switches. This capability is designed to replace countless manual iterations and experiments with faster, AI-driven decisions. The ultimate goal is to significantly accelerate research and development (R&D) pipelines, bringing novel therapies to patients with unprecedented speed.

Moderna: Streamlining complex communications and data synthesis

Moderna, a company that dramatically demonstrated the power of rapid innovation during the recent global health crisis, has successfully integrated sophisticated AI agents across various departments. These agents are tasked with assisting in a diverse range of critical functions. This includes drafting complex regulatory documents, a notoriously time-consuming and meticulous process, and personalizing patient communications, ensuring clarity and relevance for individuals. Furthermore, Moderna's AI agents are adept at synthesizing intricate datasets across their legal, medical, manufacturing, and commercial teams. This cross-functional data integration empowers better decision-making and operational efficiency throughout the organization.

Pfizer: Optimizing clinical trials and global supply chains

Pfizer, an early and enthusiastic adopter of AI technologies, has been at the forefront of using intelligent systems to improve critical areas like clinical trial management. Their AI systems can predict patient enrollment rates with greater accuracy and identify potential dropout risks, leading to more efficient trial timelines and reduced costs. Beyond R&D, Pfizer has also strategically deployed AI to enhance its global supply chain and optimize complex vaccine distribution strategies. This intelligent oversight ensures that vital medicines reach those in need promptly and effectively, even on a global scale.

Other key players and strategic engagements

While specific deployment details are often proprietary, other major players are actively exploring or contributing to the agentic AI ecosystem:

  • Novartis: This pharmaceutical giant has implemented AI to significantly improve demand forecast accuracy within its supply chain operations. Accurate forecasting is crucial for minimizing waste and ensuring product availability.
  • Genentech: Demonstrating a commitment to the responsible evolution of AI in life sciences, Genentech has provided seed funding for the Pistoia Alliance's initiative. This initiative aims to advance the safe and ethical adoption of agentic AI, indicating Genentech's role in shaping the technology's standards and protocols for R&D.
  • NVIDIA: In short, NVIDIA is positioning itself as the central infrastructure and platform provider for the next generation of Agentic AI by fostering an open ecosystem. It currently has integrations with leading industry players like Accenture, Cadence, CrowdStrike, Deloitte, EY, Oracle, Palantir, Perplexity, ServiceNow, Siemens, Synopsys, and Zoom are integrating NVIDIA's models for workflows in manufacturing, cybersecurity, software development, and more.

Medable

Medable has been a prominent voice in the agentic AI shift for clinical trials, noting that AI has evolved from requiring users to prompt it to pre-emptively identifying bottlenecks and safety risks — operating autonomously across multi-step actions with minimal human intervention. The company has built out a full Agent Platform specifically engineered for clinical development, with deep GxP, regulatory, and operational expertise baked in. The platform follows a four-step operational model: Connect (integrating clinical systems for real-time data flow), Assist (using pre-configured or custom-built agents to automate tasks), Verify (with human-in-the-loop or fully autonomous options), and Evolve (continuously improving with built-in verification and quality assurance designed for clinical development).

Medable currently fields three specialized agents, plus a co-development program for custom builds:

CRA Agent (Site Monitoring): Medable's CRA Agent is an AI-driven solution that proactively identifies and prioritizes site risks, generates comprehensive pre-visit summaries, and provides actionable recommendations to enhance trial oversight and compliance. It unifies CTMS, RTSM, EDC, labs, consent, and safety data into one view, turning manual checks into automated insights that instantly highlight which sites are on track and where intervention is needed. The platform maintains human-in-the-loop oversight, providing a transparent reasoning trail showing why each action is advised. Medable estimates that CRA agents can take on up to 90% of the tactical and administrative work a CRA handles on a daily basis — from sending site-specific emails and reminders to tracking responses and updating systems — freeing teams to focus on the strategic decisions that move trials forward.

eTMF Agent (Trial Master File Management): Medable's eTMF agents take on the high-volume work of organizing and filing trial documents, operating continuously across studies so teams can move from manual execution to oversight. The agent automates document intake from inbox to eTMF, with intelligent classification, metadata extraction, and compliant filing — backed by confidence scoring and multilingual support for global scale. The platform delivers 60% time savings per TMF document for classification and is designed to comply with all global regulations including FDA 21 CFR Part 11, ICH E6 (R2), and GDPR, with every action tracked for clear traceability so documentation is inspection-ready without extra effort.

PI Summary & Review Agent: The PI Summary & Review Agent acts as an intelligent assistant that continuously monitors eCOA and Medable-collected participant data and prepares the Principal Investigator for review and sign-off. It centralizes the effort for eCOA data by summarizing each participant's most recent data, making remote oversight seamless — addressing regulatory expectations for satisfactory oversight of remotely captured data. Critically, the review and sign-off process happens without blocking site or participant activity, so trials keep moving while review stays on track, with full transparency through underlying participant data that can be reviewed and approved before signing.

Beyond these pre-built agents, Medable also offers a co-development program allowing sponsors and CROs to bring their own ideal agent to life by working alongside Medable's team to design, refine, and deploy exactly what their trials require.

‍Transforming the pharma value chain: Key use cases of agentic AI

The power of agentic AI lies in its ability to be goal-driven, plan actions, reason through problems, and execute tasks autonomously or semi-autonomously. This capability is profoundly transforming multiple areas of the pharmaceutical value chain.

1. Research and development (R&D)

Agentic AI is poised to redefine how drugs are discovered and developed.

  • Accelerating Scientific Discovery: Multi-agent systems can analyze vast pools of research, forming novel hypotheses, and proposing new research goals by extrapolating beyond existing sources.
  • In Silico Compound Design: Agents autonomously screen millions of molecules, analyze structures, predict efficacy and toxicity, and design novel drug compounds, significantly shortening the discovery timeline.
  • Target Prioritization and Optimization: Advanced reasoning, tool use, and execution to accelerate multi-step processes like identifying and prioritizing the best drug targets for specific diseases.

2. Enhancing clinical trials

Within drug development, clinical trials are can often be critical, costly, and bottlenecked stage in drug development. Agentic AI offers solutions to many of these challenges and is a huge opportunity to improve drug development.

  • Patient recruitment: Agents analyze fragmented data (EHRs, registries) to identify eligible patients with high precision, forecast enrollment trends, and automate personalized outreach.
  • Site and safety monitoring: Agentic AI systems can monitor trial data in real-time to predict potential adverse events, issue proactive alerts, and recommend immediate "next-best actions" to enhance patient safety.
  • Data management and reconciliation: Agents continuously monitor, standardize, and validate trial data across multiple sources, for example, identifying that a "heart attack" in one system is the same as a "myocardial infarction" in another, reducing errors and accelerating decision-making.

3. Optimizing commercial and operational processes

Beyond R&D, agentic AI is bringing unprecedented efficiency to the commercial and operational aspects of pharmaceutical companies.

  • Accelerating regulatory submissions: Agents automate the complex process of gathering, formatting, and validating data for documents like INDs and NDAs, ensuring compliance and speeding up approval timelines.
  • Market research and intelligence: Agents enable teams to engage with data flexibly, generate complex analyses on demand, and integrate new signals from social media, CRM systems, and other sources to get faster insights.
  • Supply chain management: Agents continuously monitor logistics, inventory, and production schedules, adjusting orders and rerouting deliveries autonomously to maintain production continuity and mitigate risks.
  • Pharmacovigilance (Drug safety): Agents enhance pharmacovigilance by efficiently processing and classifying adverse event reports, and streamlining the monitoring and reporting process.

The Road ahead: Embracing an intelligent ecosystem

The adoption of agentic AI marks a pivotal moment for the pharmaceutical industry. It promises to move beyond simple automation to create truly intelligent ecosystems capable of accelerating innovation, improving patient outcomes, and optimizing every facet of drug development and delivery. As this technology continues to mature, we can expect to see even more sophisticated applications that push the boundaries of what's possible in healthcare.

The future of pharma is undeniably intelligent, driven by agents that learn, adapt, and act to unlock unprecedented potential.

‍

‍